🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

70 results for “autologous” Clear

  1. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  2. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  3. Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

    Pari Pharma GmbH

    Inclusion Body Myositis

    phase 2 other active

    1 trial

  4. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  5. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  6. Intracavernosal administration of autologous ADRC

    The First People's Hospital of Lianyungang

    Erectile Dysfunction

    phase 2 other completed

    1 trial

  7. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  8. KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

    Kyverna Therapeutics

    ANCA-IgG-positive ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  9. LIMBAL STEM CELLS, AUTOLOGOUS

    Fondazione Telethon ETS

    low back pain

    phase 2 small molecule active

    1 trial

  10. LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa Dystrophica

    phase 2 mab completed

    1 trial

  11. Rabipur Polvere e solvente per soluzione iniettabile in siringa preriempita. Vaccino rabico (inattivato)., TICOVAC 0,25 ml per uso pediatrico Sospensione iniettabile in una siringa preriempita Vaccino (virus intero, inattivato) contro l'encefalite da zecca, AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4+ T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomye

    Fondazione Telethon ETS

    X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)

    phase 2 small molecule active

    1 trial

  12. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  13. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial

  14. Transplantation of Autologous stem cell [MNCs] .

    Hospital Authority, Hong Kong

    Spinal Cord Injury.

    phase 2 mab active

    1 trial

  15. Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  16. autologous adipose-derived mesenchymal stem cell transplantation

    Hospital Authority, Hong Kong

    Aging Problems

    phase 2 mab active

    1 trial

  17. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  18. autologous dendritic cells pulsed with tumor lysate antigen Vaccine

    NORTHWEST BIOTHERAPEUTICS INC

    Giant Cell Glioblastoma

    phase 2 mab terminated

    1 trial

  19. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial

  20. autologous skin fibroblasts

    United Therapeutics Europe Ltd

    Wounds and Injuries

    phase 2 mab active

    1 trial

  21. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  22. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  23. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial

  24. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources